|
Onyx Names Elizabeth Tillson Vice President, Regulatory Affairs RICHMOND, Calif., Oct. 8 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - news) announced today the appointment of Elizabeth Tillson to the newly created position of Vice President, Regulatory Affairs. Ms. Tillson joins the company from Arriva Pharmaceuticals, Inc. where she held the position of Vice President, Regulatory Affairs. ``Elizabeth will oversee all aspects of the company`s regulatory operations, playing an integral role in the advancement of Onyx`s products, including ONYX-015 and our small molecule Raf kinase inhibitor, BAY 43-9006,`` said Hollings Renton, Chairman and Chief Executive Officer of Onyx. ``Elizabeth brings considerable industry experience to Onyx, and her presence will play an important role particularly as we move forward with the clinical development of ONYX-015.`` In her previous position with Arriva Pharmaceuticals, Ms. Tillson was responsible for regulatory affairs, quality assurance and quality control, as well as pre-clinical and clinical studies. Before that, she served as Vice President of Regulatory Affairs at Bachem California, Inc. and as Director of Quality at Chiron Vision Corporation. She came to Chiron Vision from BioSeparations where she was Director of Scientific Affairs. Earlier, at Chiron Corporation, she held positions of increasing responsibility including Associate Director of Regulatory Affairs, Manager of Regulatory Affairs, Project Manager, and Manager of Regulatory Affairs. Ms. Tillson received her Regulatory Affairs Certification in 1997 and is a Certified Quality Auditor. She received her B.S. and M.S. degrees from the University of Illinois, and earned her Ph.D. in Cell Biology from University of Illinois through its Public Health Service Trainee Fellowship Program. Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies. For more information about Onyx`s pipeline and activities, visit the Onyx Web site at www.onyx-pharm.com. This press release may contain certain forward-looking statements regarding the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company`s expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, and changes in the status of the company`s collaborative relationships, as well as the risk factors listed from time to time in the company`s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company. SOURCE: Onyx Pharmaceuticals, Inc. |
|
| aus der Diskussion: | onyx pharmaceut. im juhu musterdepot! |
| Autor (Datum des Eintrages): | panik (09.10.01 19:53:52) |
| Beitrag: | 40 von 229 (ID:4599582) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |